Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 17,226

Document Document Title
WO/2016/038104A1
The present invention concerns novel non-natural amino acids, more particularly non-natural analogs of arginine, ornithine or lysine, their process of preparation and their uses. In particular, such novel amino acids have the formula (I)...  
WO/2016/038383A1
A conjugate comprising a PBD dimer linked from the tether joining the two PBD units, wherein the linker is of formula (A1) : (Formula (A1)) wherein RN1 is selected from H and C1-4 alkyl; L is a linker connected to a cell binding agent; C...  
WO/2015/191951A3
The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.  
WO/2016/029324A1
Novel azasulfuryl-containing peptidomimetics capable of inhibiting CD36 activity are disclosed. Use of these azasulfuryl-containing peptidomimetics for the treatment of CD36-related diseases, disorders or conditions, including TLR2-media...  
WO/2016/033602A1
Polypeptides, such as a multi-valent polypeptide designated svD2, useful in pharmaceutical compositions for stimulation of the adaptive arm of the immune system. svD2 demonstrated in vivo activity in a syngeneic mouse model. svD2 is biol...  
WO/2016/026458A1
Provided are an anticancer compound comprising a fissionable linking group specifically activated in a tumor microenvironment, and use thereof. The anticancer compound is as represented by the following formula, wherein, R1 is a normal f...  
WO/2016/024131A1
A Gadd45β/MKK7 inhibitor for use in a method of treating a resistant haematological malignancy, combinations of said inhibitor with a further anti-cancer agent and related methods of use.  
WO/2016/021191A1
The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example ...  
WO/2016/022821A1
The present invention relates to methods of treating a patient who has colorectal cancer and to methods of reducing the likelihood that a patient will develop or experience a recurrence of colorectal cancer. The methods comprise a step o...  
WO/2016/022664A1
The present invention relates to polyamide compounds and their use in pharmaceutical compositions and in medical applications for the treatment of human papillomavirus infections and/or polyomavirus infections.  
WO/2016/021615A1
Provided are: an agricultural and horticultural bactericide having an agricultural and horticultural bactericidal activity; a compound that is represented by formula (1) and is employed as an effective component of said bactericide, and ...  
WO/2016/015160A1
Cyclic urea compounds as Granzyme B inhibitors, compositions that include the compounds, and methods for using the compounds. Methods for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and d...  
WO/2016/015159A1
Azaindoline compounds as granzyme B inhibitors, compositions that include the compounds, and methods for using the compounds. Methods for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and d...  
WO/2016/014113A1
Certain phosphonic acid salts heated at temperatures over 200°C generate thermally stable, highly efficient flame retardant materials well suited for use as flame retardant additives in polymers. Various methods for preparing flame reta...  
WO/2016/011201A2
The present specification discloses APY cyclic peptides having EphA4 antagonistic activity, pharmaceutical compositions containing such EphA4 antagonists, and methods and uses of treating an EphA4-based disease, disorder or pathology in ...  
WO/2016/009341A1
The present invention provides thioredoxin (TRX) mimetic prodrugs, more particularly, derivatives or analogues of the amino acid sequence Cys-Pro-Cys or A1 -Cys- A2 -Pro-A3 -Cys-A4 wherein A1 to A4 each independently is either absent or ...  
WO/2016/008946A1
A compound of formula (I) or a pharmaceutically acceptable derivative thereof, (formula 1) wherein R1,R2, R3, R4, R5, X, m and n are defined in the specification; a process for preparing such compounds; a pharmaceutical composition compr...  
WO/2015/179441A3
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential pro...  
WO/2016/007091A1
Various aspects of the present invention relate to a peptide based biomaterial for visualization by SHG microscopy. In particular the invention relates to the use of short peptides as a non-linear optical (NLO) material for second harmon...  
WO/2016/001042A1
The invention relates to a process for solution-phase synthesis of D-Arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide , an active ingredient used for both common and rare diseases including a mitochondrial targeted therapy for ...  
WO/2016/004067A1
The present application relates to methods and compositions for increasing the bioavailability and/or stability of aromatic-cationic peptides. In some embodiments, the aromatic-cationic peptide comprises D-Arg-2'6'-Dmt-Lys-Phe-NH2.  
WO/2015/198505A1
Provided are: a method for industrially advantageously producing a high-purity pentapeptide; and a production intermediate thereof. A compound represented by formula (1) or a salt thereof. (In the formula, R1 represents an alkyl group or...  
WO/2015/197723A1
The invention relates to a process for solution-phase synthesis of D-Arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide , an active ingredient used for both common and rare diseases including a mitochondrial targeted therapy for ...  
WO/2015/197309A1
The present invention is related to a novel and improved process for the manufacture of compounds of formula (I) or salts thereof herein designated as benzylsulfonyl-Ser-X-4-amidinobenzylamide, wherein R is a C1 to C6 linear or branched ...  
WO/2015/200322A1
In certain embodiments, the invention relates to methods for treating migraine (e.g. episodic migraine, chronic migraine, retinal migraine, ophthalmoplegic migraine, acephalgic migraine, migrainous disorder, menstrual migraine, abdominal...  
WO/2015/200656A1
A short chain polypeptide having antioxidant activity is provided. The short chain polypeptide has 2 to 4 amino acids bonded to form a polypeptide chain having an amine- terminal end and a carboxyl terminal end; wherein a net charge of t...  
WO/2015/200305A1
The present disclosure relates to methods for making asunaprevir, useful treatment of Hepatitis C virus (HCV) infection, and its intermediates.  
WO/2015/194205A1
Disclosed is a cyclic dipeptide-containing composition comprising specific amounts of: tyrosine-containing cyclic dipeptides selected from the group consisting of cyclotryptophanyltyrosine, cycloseryltyrosine, cycloprolyltyrosine, cyclot...  
WO/2015/194035A1
Disclosed is a cyclic dipeptide-containing composition comprising specific amounts of: tyrosine-containing cyclic dipeptides selected from the group consisting of cyclotryptophanyltyrosine, cycloseryltyrosine, cycloprolyltyrosine, cyclot...  
WO/2015/189791A1
Disclosed herein are novel compounds of formula (I) as described herein, and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) com...  
WO/2015/192052A1
Disclosed herein are compounds having activity as EGFR inhibitors. In some examples, the compounds can comprise an EGFR binding moiety; a linker; and a detectable moiety, therapeutic moiety, or a combination thereof. Also provided herein...  
WO/2015/187540A1
Peptide-drug conjugates comprising p-aminobenzyl carbamoyl or p-aminobenzolyl carbonate self-immolating linkers are disclosed. The peptide-drug conjugates comprise a peptide moiety that can be cleaved by cellular proteases, bound to the ...  
WO/2015/157535A3
Disclosed are peptides that contain up to about 35 amino acids, including a plurality of aromatic amino acid residues and either (i) an amino acid residue that is phosphorylated or sulfated, or (ii) an amino acid comprising an ester-moie...  
WO/2015/181688A1
The peptides have the general following formula: X–Pro*–Pro*–Xaa–Y in which: •Xaa is selected from Leucine (Leu, L), Arginine(Arg, R), Lysine (Lys, K), Alanine (Ala, A), Serine (Ser, S), and Aspartic acid (Asp, D); •At the N ...  
WO/2015/183985A2
Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of naphthoquinones, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutica...  
WO/2015/183984A2
Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of tocopherol, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically a...  
WO/2015/183963A2
Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of redox-active parabenzoquinones (RPBQs), and/or naturally or artificially occurring derivatives, anal...  
WO/2015/183995A2
Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues...  
WO/2015/183978A1
Provided are peptide analogs, pharmaceutical compositions comprising such compounds, and methods of treating cancer with such compounds.  
WO/2011/107948A3
The invention relates to ligands of insulin degrading enzyme and to their uses. The ligands of the invention are non peptidic and bind specifically to the exosite of insulin degrading enzyme. They are useful, in particular a use in the p...  
WO/2015/112093A3
The present invention relates to peptidomimetics of the formula (I) or (I)c wherein L1, L2, L3, R1, R2, R3, R4, R5, R6, n, m, Q, X, Ζ1 and Z2 are defined as mentioned in the description and to salts and solvates of each of these compoun...  
WO/2015/174500A1
[Problem] To provide a thickening composition that does not lose viscosity even in the presence of organic acids such as ascorbic acid and salts thereof. [Solution] A thickening composition containing a polyhydric alcohol, water, and org...  
WO/2015/173802A1
The present invention is directed to a peptide conjugate comprising an alpha-amino protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-acid long derived from the C'-terminus of PAR-1, or an active variant the...  
WO/2015/112980A3
Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices agains...  
WO/2015/158306A1
Provided are a glyoxalase I irreversible inhibitor as represented by the formula I, a preparation method therefor, and uses thereof. In the present invention, an irreversible inhibitor reacts with glyoxalase I in a covalent bond mode so ...  
WO/2015/155976A1
As an anti-tumor drug having an excellent anti-tumor effect and excellent safety and also having an excellent therapeutic effect, an antibody-drug conjugate is provided, said conjugate being characterized by being produced by linking an ...  
WO/2014/134562A9
The disclosure provides methods of preventing, ameliorating or treating disruption of mitochondrial function and symptoms thereof. The methods provide administering aromatic-cationic peptides in effective amounts to prevent, treat or ame...  
WO/2015/154029A1
The present invention provides a family of novel cytotoxic pentapeptides. These compounds show potent antitumor activities against several cancer lines. The antibody-drug conjugates prepared from those pentapeptides can efficiently kill ...  
WO/2015/149607A1
Disclosed are a tripeptide epoxyketone compound, a preparation method thereof, and a use thereof in the preparation of anti-tumour drugs.  
WO/2015/126269A4
The invention relates to a method of synthesis of a biopolymer derivative, preferably a chitosan derivative, comprising the formation of a peptide bond. The invention also relates to the biopolymer derivative, and use of the biopolymer d...  

Matches 451 - 500 out of 17,226